Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience.
about
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaVinculin phosphorylation differentially regulates mechanotransduction at cell-cell and cell-matrix adhesionsDrug-induced photoallergic and phototoxic reactions - an update.Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature.Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia.C-kit mutations determine dasatinib mechanism of action in HMC-1 neoplastic mast cells: dasatinib differently regulates PKCδ translocation in HMC-1(560) and HMC-1(560,816) cell lines.A newborn with teratogenic effect of imatinib mesylate: a very rare case reportLong-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients.Nilotinib-induced panniculitis in a patient with chronic myelogenous leukaemia.Ponatinib-induced widespread ichthyosiform eruption.Multiple squamous cell carcinomas following introduction of nilotinib.Imatinib mesylate-induced pseudoporphyria in two children.Xanthelasma palpebrarum: a new side effect of nilotinib.
P2860
Q26749324-B2B8D0ED-DCC1-441F-A133-C7A0320A28E0Q30577227-CA95EFBE-7D36-4EA7-A465-A452DBB28D5CQ38189112-3B7EA701-05B9-4A71-99CD-C938F1AB3251Q38246305-E93547EF-8ADD-4F7A-9F3F-F3325DE75785Q38370667-6EEB3D7E-2F39-481A-AA8A-359C7C59BABBQ38392679-B25F721F-646F-44D9-8491-E52A62C1F5DDQ38852257-F248F966-30F9-454F-B89B-6D57E5B4E4F1Q42756487-914043FC-1317-4E95-8029-AB45FA576072Q47561716-6AD658B2-5EF2-495F-ABA8-CCAF3E2BFAC4Q50213000-D22A6489-D082-4D17-80AB-12D828D89EE7Q53709484-7807F854-8B07-4FE3-9314-7C0EA04D60C6Q54327179-B4D1B7B8-B115-4E0F-B6F5-223D7BD99029Q54345379-B1346B00-4C80-4F6D-AACE-F456A0C2D5FDQ55032171-E2EE85CF-46BF-4642-9BC5-1368C3788507
P2860
Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Imatinib, dasatinib and niloti ...... is on our clinical experience.
@en
type
label
Imatinib, dasatinib and niloti ...... is on our clinical experience.
@en
prefLabel
Imatinib, dasatinib and niloti ...... is on our clinical experience.
@en
P2860
P356
P1476
Imatinib, dasatinib and niloti ...... sis on our clinical experience
@en
P2093
P2860
P304
P356
10.1111/JDV.12172
P577
2013-04-24T00:00:00Z